Sustained anti-osteoporotic action of risedronate compared to anti-RANKL antibody following discontinuation in ovariectomized mice

Bisphosphonates and the anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody denosumab are effective anti-resorptive drugs commonly prescribed for osteoporosis. Both drugs may, however, have intolerable side effects; so, it is critical to examine their residual efficacy such as...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Bone Rep
Päätekijät: Omiya, Toshinobu, Hirose, Jun, Omata, Yasunori, Tominari, Tsukasa, Inada, Masaki, Watanabe, Hisato, Miyamoto, Takeshi, Tanaka, Sakae
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7305378/
https://ncbi.nlm.nih.gov/pubmed/32577437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bonr.2020.100289
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia